A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder-Reference-Cited by-同舟云学术

A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder

Published:2022-09 Issue: Volume:128 Page:104275
ISSN:0891-4222
Container-title:Research in Developmental Disabilities
language:en
Short-container-title:Research in Developmental Disabilities

Author:

Khoodoruth Mohamed Adil Shah,Ouanes Sami,Khan Yasser Saeed

Funder

Qatar National Library

Publisher

Elsevier BV

Subject

Clinical Psychology,Developmental and Educational Psychology

Reference36 articles.

1. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder;Adler;Depression and Anxiety,2009

2. The serotonin-1A receptor in anxiety disorders;Akimova;Biological Psychiatry,2009

3. Polypharmacy in the management of attention-deficit/hyperactivity disorder in children and adolescents: a review and update;Baker;Journal of Child and Adolescent Psychopharmacology,2021

4. Society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder;Barbaresi;Journal of Developmental and Behavioral Pediatrics,2020

5. Reasons why children and adolescents with attention-deficit/hyperactivity disorder stop and restart taking medicine;Brinkman;Academic Pediatrics,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Advancing understanding and care for individuals with developmental disabilities in the Middle East;Research in Developmental Disabilities;2024-10

2. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study;Journal of Child and Adolescent Psychopharmacology;2024-04-01

3. Exploring the epigenetic landscape: The role of 5-hydroxymethylcytosine in neurodevelopmental disorders;Cambridge Prisms: Precision Medicine;2024

4. The shared genetic risk factors between Tourette syndrome and obsessive-compulsive disorder;Frontiers in Neurology;2023-10-13

5. Drugs possessing aryloxypropanamine pharmacophore, duloxetine, dapoxetine and propranolol, increase allopregnanolone in rat brain: Possible involvement of allopregnanolone in their central nervous system effects;Steroids;2023-10